NMPA approves anti-PD-1 monoanti-relylibeads in Baiji Shenzhou for the treatment of locallate or metastatic urethral skin cancer

Baiji Shenzhou announced that its anti-PD-1 antibody tislelizumab (tislelizumab) has been approved by the State Drug Administration of China (NMPA) for pD-L1 high expression, during or after platinum-containing chemotherapy or in patients with local advanced or metastatic urethra cancer (UC) who progressed during or after new or platinum-containing chemotherapy-assisted therapyreliance monitoma was first approved by NMPA for classic Hodgkin's lymphoma (cHL) in December 2019The approval for UC patients is the second indication of reilly-beaded monotomaandoma and the first in the solid tumorThe NMPA Drug Evaluation Centre (CDE) has previously conducted a priority review of its application for new complementary drugs (sNDA)NMPA approval is based on the single-arm, multi-center 2 clinical results of the trelizumab in Chinese and Korean PD-L1 plus, local late or metastatic UC patients who have previously received platinum-containing chemotherapyThe results showed that the objective mitigation rate (ORR) of the forer-bead singad was 24.8% and the full response rate (CR) was 9.9%urethra cancer is by far the most common bladder cancer, more than 90% of bladder cancer patients are urethra skin cancerIn 2019, there were about 62,000 new cases of bladder cancer in the countryTislelizumab (BGB-A317) is a human-derived IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fc-R on macrophagesIn preclinical studies, it has been shown that binding to FcsinR on macrophages can impair the antitumor activity of PD-1 antibodies